Higher Accumulation of Visceral Adipose Tissue Is an Independent Risk Factor for Hepatocellular Carcinoma among Viral Hepatitis Patients with Non-Cirrhotic Livers.
hepatitis B virus
hepatitis C virus
hepatocellular carcinoma
metabolic syndrome
visceral adipose tissue
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
28 Nov 2021
28 Nov 2021
Historique:
received:
07
11
2021
accepted:
26
11
2021
entrez:
10
12
2021
pubmed:
11
12
2021
medline:
11
12
2021
Statut:
epublish
Résumé
This study aimed to determine the risk factors for hepatocellular carcinoma in non-cirrhotic livers among viral hepatitis patients. A total of 333 HCC cases, including 69 hepatitis B virus (HBV)-related and 264 hepatitis C virus (HCV)-related, were divided into cirrhotic (Fibrosis-4 [FIB-4] index > 3.25) and non-cirrhotic groups (FIB-4 index ≤ 3.25). The clinical characteristics of the two groups were compared. The independent risk factors for the development of HCC were analyzed using logistic regression analysis. The patients with HBV-related HCC were significantly younger, had better Child-Pugh scores, lower FIB-4 index and Mac-2 binding protein glycosylated isomers (M2BPGi) levels, more progressive cancer stage, and higher alpha-fetoprotein (AFP) levels than those with HCV-related HCC. Diabetes mellitus and hypertension were less common in patients with HBV-related HCC. The non-cirrhotic group with HBV-related HCC had a higher visceral adipose tissue index (VATI), better Child-Pugh score, and higher hemoglobin A1c (HbA1c), whereas the one with HCV-related HCC had a higher proportion of men, higher VATI, better Child-Pugh score, higher HbA1c, and a higher prevalence of hypertension, than the corresponding cirrhotic groups. Logistic regression analyses demonstrated that age, male sex, VATI, HbA1c, the presence of hypertension, and HBV etiology were independent risk factors for HCC in a non-cirrhotic liver. A high accumulation of VAT is a risk factor for HCC in patients with non-cirrhotic livers.
Identifiants
pubmed: 34885089
pii: cancers13235980
doi: 10.3390/cancers13235980
pmc: PMC8657094
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Clin Gastroenterol Hepatol. 2006 Mar;4(3):369-80
pubmed: 16527702
Metabolism. 2014 May;63(5):607-17
pubmed: 24629562
J Clin Invest. 2011 Jun;121(6):2094-101
pubmed: 21633177
Cancer. 2004 Sep 1;101(5):1009-17
pubmed: 15329910
J Hepatol. 2017 Aug;67(2):302-309
pubmed: 28336466
Cancer Control. 2017 Jul-Sep;24(3):1073274817729245
pubmed: 28975830
J Viral Hepat. 2021 Mar;28(3):493-507
pubmed: 33305479
Oncotarget. 2018 Feb 16;9(18):14058-14067
pubmed: 29581826
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
N Engl J Med. 2011 Sep 22;365(12):1118-27
pubmed: 21992124
Hepatology. 2011 Mar;53(3):1020-2
pubmed: 21374666
Cancer Res. 1998 Jan 15;58(2):348-51
pubmed: 9443416
Am J Gastroenterol. 2017 May;112(5):740-751
pubmed: 27725647
Hepatology. 2006 Jun;43(6):1317-25
pubmed: 16729309
Hepatol Res. 2006 Mar;34(3):163-9
pubmed: 16478676
Biometrics. 2000 Sep;56(3):909-14
pubmed: 10985236
Hepatology. 2009 Sep;50(3):957-69
pubmed: 19585655
Biochim Biophys Acta. 2010 Mar;1801(3):209-14
pubmed: 19948243
Cancers (Basel). 2021 Mar 26;13(7):
pubmed: 33810624
J Clin Gastroenterol. 2002 Nov-Dec;35(5 Suppl 2):S72-8
pubmed: 12394209
Hepatol Res. 2010 Apr;40(4):376-82
pubmed: 20236359
Endocr Rev. 2000 Dec;21(6):697-738
pubmed: 11133069
Hepatol Res. 2019 Oct;49(10):1109-1113
pubmed: 31336394
Hepatology. 1997 Sep;26(3):598-604
pubmed: 9303488
Hepatology. 2018 Jan;67(1):358-380
pubmed: 28130846